Elevated CSN6 may be prognostic for poor survival colorectal cancer
the ONA take:
A study from The University of Texas MD Anderson Cancer Center identified a protein, CSN6, a subunit of a protein complex known as COP9 signalsome, that correlated with poor survival in patients with colorectal cancer. The researchers found that elevated CSN6 is a biomarker for worse recurrence-free survival in patients with colon cancer.
CSN6 is normally regulated through the EGFR and ERK signaling pathways. When overexpressed via ERK2 in particular, it leads to deregulation of beta-catenin, a transcription factor known to be linked to cancer development.
The current standard of treatment for colorectal cancer in patients at high risk of recurrent or metastatic disease includes surgery, chemotherapy, and targeted therapies.
The researchers report that defining the molecular alterations can help guide treatment and improve clinical care.
CSN6, a subunit of a protein complex known as COP9 signalsome, correlated with poor survival in patients with colorectal cancer.
Sign Up for Free e-newsletters
- Avoiding the ED: Planned Strategies for Unplanned Urgent Cancer Care
- NP-Led Clinics Improved Phase 1 Oncology Study Operations, Outcomes
- Art as Palliative Care: Bedside Intervention Improves Pain, Anxiety, Mood in Hospitalized Cancer Patients
- Unprotected Sex After Chemotherapy
- Mindfulness Training May Improve End-of-Life Conversations in Advanced Cancer
- Exercise Habits Influence Mortality in Adult Survivors of Childhood Cancer
- A Call for More Tailored Cancer Education Programs to Improve Screening
- Aligning Patient Goals With End of Life Treatment Decisions
- Study Suggests Greater Focus on the Needs of Family Caregivers of Patients With Cancer
- First Antibody-Based Treatment Regimen Approved for First-Line Treatment of Multiple Myeloma
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|